



# Meeting Agenda Materials

## Annual General Meeting of Shareholders

June 18<sup>th</sup> , 2025

PT Pyridam Farma Tbk

[pyfa.co.id](http://pyfa.co.id)

*Disclaimer:*

*In the event of amendment or addition to Agenda to the Annual General Meeting of Shareholders, the company will inform the matter to Shareholders through the Company's website.*

## Agenda 1 (1/2)

Approval of the Annual Report, Sustainability Report and Ratification of the Company's Financial Statements for the financial year which ended on December 31st, 2024 as well as granting of full release and discharge of responsibilities (volledig acquit et de charge) to the members of the Board of Directors and members of the Board of Commissioners for the management and supervisory actions carried out for the financial year which ended on December 31st, 2024.

---

## Regulations:

- Article 13 paragraph (5) letter a and Article 13 paragraph (6) Company's Article of Association
- Article 66, Article 67, Article 68, and Article 69 Law No. 40 of 2007 on Limited Liability Company ("**Company Law**")

## Agenda (2/2)

### Elucidation

- In the 2025 Annual General Meeting of Shareholders (the “Meeting”) will be presented and sought for approval/ratification from the Shareholders for the Company’s Annual Report of the book which ended on December 31<sup>st</sup>, 2024, among others the supervisory duties of the Board of Commissioners for the book which ended on December 31<sup>st</sup>, 2024 and the Company’s Financial Statements for the book which ended on December 31<sup>st</sup>, 2024 which have been audited by Public Accounting Purwanto, Sungkoro & Surja, a member firm of EY, in all material respects, the consolidated financial position of PT Pyridam Farma Tbk and its subsidiaries as of December 31<sup>st</sup>, 2024, and its consolidated financial performance and its consolidated cash flows for the year then ended, in accordance with Indonesian Financial Accounting Standards, as stated in its report Number 00526/2. 1032/AU.1/05/1810-1/1/III/2025, dated March 31<sup>st</sup>, 2025
- The Annual Report, Sustainability Report and Financial Statement of PT Pyridam Farma Tbk. can be downloaded in the website ([www.pyfa.co.id](http://www.pyfa.co.id)).

## Agenda 2

Determination of the allocation of the Company's net profit/loss for the financial year which ended on December 31st, 2024.

---

### Regulations:

- Article 13 paragraph (5) letter b Company's Article of Association
- Article 70 and Article 71 Company Law

#### Elucidation

- The Company's Net Loss for the financial year ended December 31<sup>st</sup>, 2024 at the amount of IDR 330.246.365.580,-.
- More information regarding the Company's Net loss for the book of 2024, can refer to the 2024 Financial Statements as available on the Company's website.

## Agenda 3

Determination of Remuneration of Members of the Board of Directors and Board of Commissioners of the Company for the Financial Year in 2025

---

### Regulations:

- Article 13 paragraph (5) letter e Company's Article of Association
- Article 96 paragraph (1) and (2) and Article 113 Company Law

#### Elucidation

In regards of the performance of the Board of Directors and the Board of Commissioners, and in order to maintain competitiveness and conformity with market competition conditions, it is necessary to make adjustments to the remuneration of members of the Board of Directors and Board of Commissioners of the Company.

## Agenda 4

Appointment of Public Accountant Firm to perform audit on the Company's Consolidated Financial Statements for the financial year which ended on December 31<sup>st</sup>, 2025

---

### Regulations:

- Article 13 paragraph (5) letter c Company's Article of Association
- Article 59 paragraph (1) and (2) Financial Service Authority (“**FSA GMS**”) Regulation No. 15/POJK.04/2020 on Plan and Procedures for General Meeting of Shareholders of Public Companies

#### Elucidation

Taking into account the condition of the Company, the Company still needs time to monitor and evaluate performance and to consider prospective public accountants to be appointed based on input from the Company's Board of Commissioners and the Company's Audit Committee and to consider other purposes deemed necessary in making decisions.

## Agenda 5 (1/3)

Reports on the Realization of the Use of Proceeds from the Continuing Public Offering of Pyridam Farma Sustainable Bonds I Phase II Year 2023, Public Offering of Pyridam Farma Sustainable Bonds I Phase III Year 2024, Rights Issue I (Limited Public Offering with Pre-emptive Rights) and Issuance of Series I Warrants.

---

### Regulations:

- Article 13 paragraph (5) letter f Company's Article of Association
- Article 6 paragraph (1) and (2) FSA Regulation No. 30/POJK.04/2015 on Realization Report on the Utilization of Fund from Public Offering

## Agenda 5 (2/3)

### Elucidation

- As of December 31, 2024, the Company has implemented the use of proceeds from the Public Offering of Pyridam Farma Continuing Bonds I Phase II Year 2023 in the amount of IDR 343,592,648,061, as stated in the Use of Proceeds from the Public Offering of Pyridam Farma Continuing Bonds I Phase II Year 2023, Letter No.: 005/PYFA-CS/I/2025 dated January 14, 2025.
- The Company has realized the utilization of proceeds from the Public Offering of Pyridam Farma Continuing Bonds I Phase III Year 2024 in the amount of IDR 105,299,258,721, as stated in the Report on the Realization of Use of Proceeds from the Public Offering of Pyridam Farma Continuing Bonds I Phase III Year 2024, Letter No.: 007/PYFA-CS/I/2025 dated January 14, 2025.



## Agenda 5 (3/3)

### Elucidation

- As of December 31, 2024, the Company has realized the full use of the proceeds from the Rights Issue with Pre-Emptive Rights I ("PMHETD I") amounting to IDR 1,065,099,254,694 and proceeds from the conversion of Series I Warrants into shares amounting to IDR 1,504,800, as referred to in the Report on the Realization of Proceeds from the Limited Public Offering to Shareholders for the Issuance of Series I Warrants No. 006/PYFA-CS/1/2025, dated January 14, 2025, and the Report on the Realization of Proceeds from the Rights Issue with Pre-Emptive Rights I and the Issuance of Series I Warrants No. 084/PYFA-CS/VII/2024, dated July 15, 2024.

## Agenda 6

Approval of changes of the composition of the Company's management.

---

### Regulations:

- Article 13 paragraph (5) letter (d), Article 29 paragraph (3), Article 29 paragraph (5), and Article 32 paragraph (5) of the Company's Articles of Association
- Article 94 paragraph (1) and Article 111 paragraph (1) Company Law.
- Article 3 of FSA Regulation Number 33/POJK.04/2014 concerning Board of Directors and Board of Commissioners of Issuers or Public Companies

Elucidation

Changes to the Composition of the Board of Directors and Board of Commissioners of the Company

# Attachment - curriculum vitae (CV) of Company Management Candidates



**Lee Yan Gwan**

**62 years old, Singapore citizen.**

With a Bachelor of Commerce background from Adventist University of the Philippines. Throughout his career, he has held positions as Country Director at SEAVI Indonesia Venture (1997–1998), then served as Commercial Director at SCTV (1998–2000), Director at Indika Group (1998–2000), and then as Deputy President Director at Lippo Group (2001–2002). Furthermore, he served as Senior VP at Cathay Organisation Holdings Ltd (2009–2010), Director at Newstart Health Food (2010–2018), then was appointed as President Director at PT Pyridam Farma Tbk (2020–present), Director at Rejuve Global Investment Pte. Ltd. (2022–present), and since 2024 has served as Director at Pyfa Health Singapore Pte. Ltd.

## Attachment - curriculum vitae (CV) of Company Management Candidates



With an educational background in Business Administration from The Ohio State University (2007), he began his career as an Associate at JP Morgan Asset Management (2008–2017), then served as Vice President at Korea National Pension Service from May to September 2017. Subsequently, he held the position of Deputy General Manager at PT Jakarta Setiabudi Internasional Tbk (2017–2019), and was then appointed as Director at PT Pyridam Farma Tbk (2020 – Present), as well as Director at PT Pyfa Investama Medika and PT Pyfa Aetheria Indonesia (both since 2021 – Present). He is also currently serving as Commissioner at PT Holi Pharma since 2023.

**Yenfrino Gunadi**

**40 years old, Indonesian citizen.**

## Attachment - curriculum vitae (CV) of Company Management Candidates



**Bedjo Stefanus**

**62 years old, Indonesian citizen.**

With a background in pharmaceutical science, he served as Sales Manager at PT Rajawali Nusindo (1982–1991), then served as General Manager at PT Barito Budi Pharmindo (1992–2022). Furthermore, he served as President Director at PT Errita Pharma (1998–2005), and since 2007 until now has served as President Director at PT Holi Pharma. Since 2023 until now, he has also served as Commissioner at PT Ethica Industri Farmasi and as Director at PT Pyridam Farma Tbk.

## Attachment - curriculum vitae (CV) of Company Management Candidates



**Widjanarko Brotosaputro**

**60 years old, Indonesian citizen.**

With an educational background as a medical doctor from Tarumanagara University (1991) and a Master of Management degree from Prasetiya Mulya Business School (2002), he has held various strategic positions throughout his career in the pharmaceutical industry, including: Sales Marketing Head at Novartis Biochemie (1997–2004), Chief Executive Officer (CEO) of PT Combiphar Sandoz Division (2004–2005), Compliance Officer at PT Prima Hexal (2005–2006), and Sales & Marketing Director at PT Yarindo Farmatama (Fahrenheit) (2006–2007). Subsequently, he served as VP Marketing and Director at PT Combiphar (2007–2013), continued his career as VP Marketing & Business Development at PT Meprofarm (2014–2015), Business Unit Director at PT Ikapharmindo Putramas (2016), Head of Sales, Marketing, and Business Development at PT Pyridam Farma Tbk (2017–2019), and currently serves as Director of PT Pyridam Farma Tbk since 2019, as well as President Commissioner of PT Ethica Industri Farmasi and PT Holi Pharma since 2023 to present.

## Attachment - curriculum vitae (CV) of Company Management Candidates



**Antes Eko Prasetyo**

**43 years old, Indonesian citizen.**

With an educational background in Business Management from Atma Jaya Catholic University and Mercu Buana University, He has more than 15 years of experience in the pharmaceutical industry. His professional background includes roles such as Marketing Communication for Oncology, Virology, Transplant & Anemia Businesses at PT Roche Indonesia (2008–2011), Product & DTC Manager – Adult Vaccines Business at PT GlaxoSmithKline (2011–2012), has held the positions of Business Unit Head, Business Unit Manager, and Product Manager at PT Johnson & Johnson Indonesia (2012–2016), PT Mundipharma Healthcare Indonesia (2016–2022), with the last position as Commercial Director for Ethical & Consumer Health Care (Betadine). He currently holds the position of Chief Commercial Officer at PT Pyridam Farma Tbk.

In addition, He was a lecturer and academic counselor at Atma Jaya Catholic University and as a teacher at Morning Star Academy Jakarta (2004–2007).

## Attachment - curriculum vitae (CV) of Company Management Candidates



**Sintia L. Ningsih**  
43 years old, Indonesian citizen.

With an educational background in Economics – Accounting from Tarumanagara University, she has more than 15 years of experience in the financial sector across various industries. Her professional experience includes serving as Assistant Audit Manager as her last position at KPMG Sidharta & Widjaja – a Big 4 Public Accounting Firm (2005–2010). She then held the position of Senior Finance Manager at PT Aiana Proprietary Loyalty Indonesia (2010–2017), followed by Senior Finance & Accounting Manager at PT Warner Music Indonesia (2017–2020), and Head of Reporting at PT Visionet Internasional "OVO" (2020–2021). Since 2021 until now, she has been serving as Vice President of Finance, Accounting, and Tax at PT Pyridam Farma Tbk.



## Attachment - curriculum vitae (CV) of Company Management Candidates



**Robby Yulianto**

**43 years old, Indonesian citizen.**

With a background in Bachelor of International Business from Auckland Institute of Business. He has held various strategic positions throughout his career, he served as Commissioner at PT Professional Human Resources (2007–2023), he then served as Director at PT Safe Secured Solution and PT Master Parking Indonesia, as well as Commissioner at PT Human Resources Solution and President Commissioner at PT Shield on Service, all from 2009 to 2023. Subsequently he became Director at PT The Service Line (2013-2023), followed by a Director position at PT SOS Indonesia (2014-2023). From 2016 to 2023, he also served as Director at PT Human Resources Provider. Since 2020, he has been serving as President Commissioner at PT Pyridam Farma Tbk.

## Attachment - curriculum vitae (CV) of Company Management Candidates



**Maura Linda Sitanggang**

**67 years old, Indonesian citizen.**

She earned her Bachelor's degree in Pharmacy in 1981 and obtained her professional qualification as a Pharmacist in 1982 from the Bandung Institute of Technology. She subsequently pursued doctoral studies at the University of Bath, completing her Ph.D. in 1988.

In her career, she served as Director, Inspector at the Indonesian Food and Drug Supervisory Agency (2001-2012), Short-Term Expert at the World Health Organization (2004-2010), Long-Term Expert at the United Nation Development Program (2020-2022), Director General of Pharmaceuticals and Medical Devices at the Indonesian Ministry of Health (2012–2018), continued as Chair of the Supervisory Board at the National Brain Center Hospital, Jakarta (2018–2020). Since 2022, she has been trusted as an Independent Commissioner at PT Pyridam Farma Tbk. In addition, she also serves as Chairman of the Expert Council at the Indonesian Medical Device Ecosystem Development Association (2024–present) and Member of the Supervisory Board at The Indonesian Association for the Study of Medicinals (2025–present).

## Attachment - curriculum vitae (CV) of Company Management Candidates



**Charles D. Marpaung**

**70 years old, Indonesian citizen.**

He earned his Doctorate in Monetary & International Finance from Oklahoma State University in 1993, after obtaining a Master's degree in Business and Economics from Pittsburg State University in 1988, and a Bachelor's degree in Accounting (Doktorandus) from the University of Indonesia in 1981.

Throughout his career, he has served as a Lecturer at the Graduate School of Business, Pelita Harapan University (1996–2021) and Bina Nusantara University (1997–2010). He has also served as Deputy Chair for Banking at the Indonesian Chamber of Commerce (1997–2000), Expert Staff for Economics at the Indonesian National Defense and Security Council (1998–2005), Director at Bank Agroniaga (1999–2000), and Special Expert Staff at the Ministry of Agriculture (2001–2002). In the period 2002–2007, he served as President Director of PT CMP Consulting. Since 2022 until now, he has served as an Independent Commissioner at PT Pyridam Farma Tbk.

**Note:**

*The material for this Meeting Agenda is to meet the provisions of Article 18 paragraph (1) and (2) FSA GMS, which In essence, explains that a Public Company is required to provide meeting agenda materials for shareholders that can be accessed and downloaded through the Public Company website and/or e-GMS which must be available from the date of the GMS invitation until the GMS is held with the exceptions as stipulated in Article 18 paragraph. (3), in the provisions of other opposition regulations that requires the availability of meeting agenda materials is earlier than the provisions referred to in paragraph (2), the provision of meeting agenda materials in accordance with the provisions of the other relevant regulations.*

# Thank you